ClinicalTrials.gg
CompletedNCT02027454Updated Jun 16, 2014

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

A Phase 1 interventional study of GSK1265744 and GSK1265744 matching placebo in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-16.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is being conducted to comply with the Food and Drug Administration (FDA) recommendation that all new non anti-arrhythmic drugs be assessed for cardiac repolarization effects through electrocardiographic evaluation. Therefore, this study will evaluate the effect of GSK1265744 on cardiac conduction as assessed by collection of twelve-lead continuous digital data in healthy adults. This study will evaluate the effect of three doses of GSK1265744 on the QT duration corrected for heart rate (QTc) interval as compared to placebo. Moxifloxacin will be used as a positive control in order to validate the sensitivity of the study in detecting QTc change. This study consists of three treatment periods (each separated by 21 day washout period) followed by follow-up visit 10 to 14 days post last dosing. The total duration of study including follow-up visit will be approximately 62 days. Approximately 42 subjects will be enrolled such that 34 subjects complete dosing and critical assessments.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • GSK1265744
  • HIV
  • placebo
  • cardiac repolarization
  • 12-lead ECG
  • moxifloxacin
  • QTc
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 42 is below the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females aged between 18 and 55 years of age inclusive, at the time of signing the .
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • Body weight >=50 kilograms (kg) for men and >= 45 kg for women and (BMI) within the range 18.5-31.0 kg/meter\^2 (inclusive).
  • A female subject is eligible to participate if she is of: non- defined as pre-menopausal females with a documented tubal ligation, bilateral oophorectomy or hysterectomy [for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli international unit (MlU)/mililiter (m) and estradiol \< 40 picogram/mL (\<147 picomoles/L) is confirmatory] OR has only same-sex partners, when this is her preferred and usual lifestyle.
  • Male subjects with female partners of child-bearing potential must agree to use one of the methods. This criterion must be followed from the time of the first dose of study medication until 21 days post-last dose.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • Use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • A positive pre-study drug/alcohol screen.
  • A positive test for human immuno virus antibody.
  • Subjects with an , alkaline phosphatase and >=1.5xupper limit of normal () (isolated bilirubin \<1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin >35%).
  • The subject's systolic blood pressure is outside the range of 90 to140 milimeter of mercury (mmHg) or diastolic blood pressure is outside the range of 45 to 90mmHg or heart rate is outside the range of 50 to 100 beats per minute (bpm) for female subjects or 45 to 100 bpm for male subjects.
  • Exclusion criteria for screening (a single repeat is allowed for eligibility determination): are: male subjects with Heart rate \<45 and >100 bpm and female subjects with heart rate \<50 and >100 bpm, PR \<120 and >220 milliseconds (msec), QRS duration \<70 and >120 msec, >450 msec.

Evidence of previous myocardial infarction (Does not include ST segment changes associated with repolarization).

Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular block [2nd degree or higher], Wolf Parkinson White syndrome).

Sinus Pauses > 3 seconds. Any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety for the individual subject.

Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats).

  • Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).

    Drug: GSK1265744 · Drug: GSK1265744 matching placebo · Drug: Moxifloxacin

  • Experimental
    Sequence 2

    Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).

    Drug: GSK1265744 · Drug: GSK1265744 matching placebo · Drug: Moxifloxacin

  • Experimental
    Sequence 3

    Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).

    Drug: GSK1265744 · Drug: GSK1265744 matching placebo · Drug: Moxifloxacin

  • Experimental
    Sequence 4

    Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).

    Drug: GSK1265744 · Drug: GSK1265744 matching placebo · Drug: Moxifloxacin

  • Experimental
    Sequence 5

    Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).

    Drug: GSK1265744 · Drug: GSK1265744 matching placebo · Drug: Moxifloxacin

  • Experimental
    Sequence 6

    Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).

    Drug: GSK1265744 · Drug: GSK1265744 matching placebo · Drug: Moxifloxacin

Interventions

  • White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.

  • DrugGSK1265744 matching placebo

    GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).

  • Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.

06

What researchers measure

Primary outcomes

  1. Change from baseline in QT duration corrected for heart rate by Fridericia's formulas (QTcF) for GSK1265744

    QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTcF interval will be obtained by digital electrocardiograms (ECG) obtained through 12 lead holter monitoring machine. Triplicate ECGs will be evaluated at each time point

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days)

Secondary outcomes

  1. Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), individual corrected QTc ( QTci) values, QT, QRS, and PR for GSK1265744

    Single ECG will be obtained at all timepoints during the study using an ECG machine that automatically measures PR (beginning of P wave to the beginning of the next QRS), QRS (beginning of Q to the end of the S wave), QT, and QTc intervals.

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  2. Change from baseline in heart rate (HR) for GSK1265744

    Single ECGs will be obtained at all timepoints during the study using an ECG machine that automatically calculates the heart rate. Heart rate is defined as the number of heartbeats per unit of time, usually per minute.

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  3. Change from baseline in QTcF, QTcB, QTci, QT, QRS, and PR for placebo

    Single ECGs will be obtained at all timepoints during the study using an ECG machine that automatically calculates the QTcF, QTcB, QTCi, QT, QRS, PR intervals

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  4. Change from baseline in HR for placebo

    Single ECGs will be obtained at all timepoints during the study using an ECG machine that automatically calculates the heart rate. Heart rate is defined as the number of heartbeats per unit of time, usually per minute.

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  5. Change from baseline in QTcF, QTcB, QTci, QT, QRS, and PR for Moxifloxacin

    Single ECGs will be obtained at all timepoints during the study using an ECG machine that automatically calculates the QTcF, QTcB, QTCi, QT, QRS, PR intervals

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  6. Change from baseline in HR for Moxifloxacin.

    Single ECGs will be obtained at all timepoints during the study using an ECG machine that automatically calculates the heart rate. Heart rate is defined as the number of heartbeats per unit of time, usually per minute.

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  7. Composite of pharmacokinetic (PK) parameters for GSK1265744.

    PK parameters include: area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC\[0-t\]), area under the concentration-time curve from time zero extrapolated to infinite time (AUC\[0-infinity\]), maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), apparent clearance following oral dosing (CL/F), apparent volume of distribution at steady state after oral administration (Vdz/F), and terminal phase half-life (t1/2) from plasma concentrations of GSK1265744.

    Time frame: Blood samples will be collected at following time points: Day 1 pre-dose (15 minutes prior to first dose 1), and at Day 2 pre-dose (within 15 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6.5, 8, 12, and 24 hours post last dose in each period.

  8. Composite of PK parameters for Moxifloxacin (if needed).

    PK parameters include: AUC (0-t), AUC (0-infinity), Cmax, tmax, CL/F, Vdz/f, and t1/2.

    Time frame: Blood samples will be collected on Day 2 at pre-dose, 0.5, 1, 2, 3, 4, 6.5, 8, 12, and 24 hours post last dose in each period.

  9. 12-lead ECG as a measure of safety and tolerability.

    12-lead ECGs will be performed with the subject in a semi-supine position having rested in this position for at least 10 minutes beforehand. ECGs will be obtained using an ECG machine that automatically calculates the QTcF, QTcB, QTCi, QT, QRS, PR intervals and HR.

    Time frame: Up to 62 days.

  10. Vital sign as a measure of safety and tolerability.

    Vital sign measurement include: blood pressure and heart rate.

    Time frame: Up to 62 days.

  11. Number participants with adverse events as a measure of safety and tolerability.

    AEs will be collected from the start of Study Treatment and until the follow-up contact.

    Time frame: Up to 62 days.

  12. Clinical laboratory parameters assessment as a measure of safety and tolerability.

    Clinical laboratory assessment include: hematology, clinical chemistry, urinalysis and additional parameters as needed.

    Time frame: Up to 62 days.

  13. Change from baseline in QTcF, QTcB and QTci for GSK1265744

    Single ECGs will be obtained at all timepoints during the study using an ECG machine that automatically calculates the QTcF, QTcB, and QTCi intervals.

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  14. Difference between GSK1265744 and placebo in terms of change from baseline in QTcF, QTcB and QTci.

    Difference between GSK12657744 and placebo in terms of change from baseline in QTcF, QTcB and QTci will be measured to characterize pharmacodynamic (PD) relationship between exposure of GSK1265744 and changes in QTcF, QTcB and QTci

    Time frame: Baseline on Day -1 and Day 2 for Periods 1 - 3 (49 Days).

  15. Plasma concentration profile as assessed from composite of PK parameters of GSK1265744.

    Plasma concentration profile of GSK1265744 will be assessed to characterize PK/PD relationship between exposure of GSK1265744 and changes in QTcF, QTcB and QTci. PK parameters to be assessed for plasma concentration profile are: area under the concentration-time curve from zero to 24 hours (AUC \[0-24\]), AUC (0-t), AUC (0-infinity), and Cmax.

    Time frame: Blood samples will be collected at following time points: Day 1 pre-dose (15 minutes prior to first dose 1), and at Day 2 pre-dose (within 15 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6.5, 8, 12, and 24 hours post last dose in each period.

07

Study locations

1 site
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2013
First posted
Jan 6, 2014
Start
Jan 2014
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Jun 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02027454
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 6, 2014
Start date
Jan 2014
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Jun 16, 2014

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion